PDS Biotechnology (NASDAQ:PDSB) Upgraded by Zacks Investment Research to Hold

0
43

PDS Biotechnology stock has undergone multiple analysts rating changes in the recent past.  PDS Biotechnology Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of PDS Biotechnology traded down -$0.48 on Wednesday, reaching $13.73. 0 shares of the stock traded hands, compared to its average volume of 475073. Shares of PDS Biotechnology were trading at $13.73 on Wednesday. The firm’s 50 day moving average is $13.70 and its 200 day moving average is $8.34.PDS Biotechnology has a 12 month low of $13.65 and a 12 month high of $17.85. While on yearly highs and lows, PDS Biotechnology’s today has traded high as $14.65 and has touched $13.65 on the downward trend. See More Analyst Rating at: RATING

PDS Biotechnology Earnings and What to expect: 

PDS Biotechnology last released its earnings data on August 11th, 2021. The reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.14. PDS Biotechnology has generated ($0.89) earnings per share over the last year (($0.56) diluted earnings per share). Earnings for PDS Biotechnology are expected to decrease in the coming year, from ($0.81) to ($0.91) per share. PDS Biotechnology has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, November 10th, 2021 based off prior year’s report dates.

Earnings for PDS Biotechnology are expected to decrease in the coming year, from ($0.81) to ($0.91) per share. The P/E ratio of PDS Biotechnology is -24.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of PDS Biotechnology is -24.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. PDS Biotechnology has a P/B Ratio of 11.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

PDS Biotechnology (NASDAQ:PDSB) Moving Average Technical Analysis

5 day Moving Average is $13.84 And 5 day price change is -$0.02 (-0.15%)  with average volume for 5 day average is 396,960. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $14.85 and 20 day price change is -$1.57 (-10.26%) and average 20 day moving volume is 498,765. 50 day moving average is $13.70  and 50 day price change is $2.67 ( 24.14%)  and with average volume for 50 days is : 484,516. 200 day moving average is $8.34  and 200 day price change is $11.54 (526.94%)  and with average volume for 200 days is : 1,272,427.

Other owners latest trading in PDS Biotechnology :

  • On 10/13/2021 shares held by Andesa Financial Management Inc. were 16,655 which equates to market value of $0.25M and appx 0.10% owners of PDS Biotechnology
  • On 8/23/2021 shares held by Morgan Stanley were 65,703 which equates to market value of $0.83M and appx 0.00% owners of PDS Biotechnology
  • On 8/17/2021 shares held by Worth Venture Partners LLC were 348,703 which equates to market value of $4.38M and appx 1.60% owners of PDS Biotechnology
  • In total Institutional ownership equates to Institutional Ownership Percentage: 21.33% for PDS Biotechnology

See More Analyst Rating at: RATING